Monoclonal Gammapathy Of Undetermined Significence Due To Chronic Osteomiyelitis ( A Case Report )

Year 2000, Volume: 1 Issue: 2, 39 - 41, 01.08.2000

Gürhan Kadıköylü A. Zahit Bolaman İrfan Yavaşoğlu Taşkın Şentürk

Abstract

Monoclonal gammapathy was detected in a patient who had been operated four times for osteomiyelitis in her foot and had taken antituberculoid drugs for three years. Her clinical and laboratory findings corresponded with monoclonal gammapathy of undetermined significance (MGUS). In this articile, a case with MGUS due to chronic osteomyelitis was reported.

Keywords

Osteomyelitis, monoclonal gammopathy of undetermined significence

References

• 1. Kyle RA, Rajkumar SV. Monoclonal gammopathies and related disorders.Hematology- Oncology Clinics of North America 1999;13:1181-202.
• 2. Durie BGM. Staging and kinetics of multiple myeloma. Semin Oncol 1986;13 : 300-9.
• 3. Greipp PR. Advances in the diagnosis and management of myeloma. Semin Hematol 1992 ;29 (suppl 2) :24-45.
• 4. Baldini L, Guffanti A, Cesana BM, Colombi M, Chiorboli O, Damilano I, Maiolo AT. Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. Blood 1996;87: 912-8.
• 5. Kyle RA. Monoclonal gammopathy of undetermined significance (MGUS). Baillieres Clinical Haematology 1995; 8: 761-81.
• 6. Greipp PR, Witzig TE, Gonchoroff NJ, Habermann TM, Katzmann JA, O’ Fallon WM, Kyle RA. Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. Mayo Clinc Proc 1987;62: 969-77.
• 7. Cohen HJ, Bernstein RJ, Grufferman S. Role of immune stimulation in the etiology of multiple myeloma : a case central study. American Journal of Hematology 1987;24:119-26.
• 8. Linet MS, Harlow SD, Mc Laughlin JK. A case-control study of multiple myeloma in whites: chronic antigenic stimulation, occupation and drug use. Cancer Research 1987; 47: 2978-81.
• 9. Osserman EF, Takatsuki K. Plasma cell myeloma: Gammaglobulin synthesis and structure. Medicine 1963;42: 357.
• 10. Foerster J. Plasma cell dyscrasias: general considerations. In: Wintrobe’s Clinical Hematology. Lee R, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM (Edits). 10thEd., Williams& Wilkins, Mass Publishing Co, Mýsýr, 1999;2612-25.
• 11. Kyle RA. Monoclonal gammopathy of undetermined significance. Blood Reviews 1994;8:135-41.
• 12. Tricot G. Multiple myeloma and other plasma cell disorders. In : Hematology. Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, Mc Glave P (Edits). 3rd Ed., Churchill Livingstone, Philedelphia, 2000; 1398-410.
• 13. Chelazzi G, Senaldi G. Serum Beta-2 microglobulin levels in multiple myeloma and monoclonal gammopathy of undetermined significance : a clinical study of 55 patients. Ric Clin Lab 1986;16: 538.
• 14. Zhang XG, Bataille R, Widjeners J, Klein B. Interleukin- 6 dependence of advanced malignant plasma cell dyscrasias. Cancer 1992;69:1373-6.
• 15. Kyle RA. Monoclonal gammopathy of undetermined significance and solitary plasmacytoma. HematologyOncology Clinics of North America 1997; 11: 71-87.
• 16. Witzig TE. The role of adhesion receptors in the pathogenesis of multiple myeloma.Hematology-Oncology Clinics of North America 1999;13: 1127-43.
• 17. Giraldo MP, Rubio-Felix D, Perella M, Gracia JA, Bergua JM, Gira HM. Monoclonal gammopathies of undetermined significance. Clinical course and biologic aspects of 397 cases (Abstract). Sangre 1992;36 377- 82.
• 18. Pasqualetti P, Festuccia V, Collaccianci A, Casale R. The natural history of monoclonal gammopathy of undetermined significance. A 5 to 20-year follow up. Acta Haematologica 1997; 97: 174-9.
• 19. Gavarotti P, Fortina F, Costa D, Verzetti G, Redoglia V, Boccadoro M. Benign monoclonal gammopathy presenting with several renal failure. Scand J Haematol 1986;36:115-7.
• 20. Potter M. Antigen-binding myeloma proteins of mice. Adv Immunol 1977; 25: 141.